Publications





Localization of Radiolabeled Somatostatin Analogs in the Spleen.
Clin Nucl Med 2016 Feb;41(2):e111-4
From the *Department of Nuclear Medicine, Erasmus MC, Rotterdam, the Netherlands; †Department of General and Visceral Surgery, and ‡Theranostics Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, Bad Berka; §Institute of Pharmacology and Toxicology, Jena University Hospital, Jena; ∥Laboratory of Pathology and Cytology, Zentralklinik Bad Berka, Bad Berka, Germany; and ¶Department of Radiology, Erasmus MC, Rotterdam, the Netherlands.


First-In-Human Study Demonstrating Tumor-Angiogenesis by PET/CT Imaging with (68)Ga-NODAGA-THERANOST, a High-Affinity Peptidomimetic for αvβ3 Integrin Receptor Targeting.
Cancer Biother Radiopharm 2015 May;30(4):152-9
1 THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Zentralklinik Bad Berka, ENETS Center of Excellence , Bad Berka, Germany .

THERANOSTICS-clinical aimshots in surgical warfare against well-differentiated neuroendocrine neoplasms.
Ann Transl Med 2014 Jan;2(1)
1 Internal Medicine/Gastroenterology and Endocrinology, Center for Neuroendocrine Tumors Bad Berka-ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9, 99437 Bad Berka, Germany ; 2 THERANOSTICS Center for Molecular Radiotherapy and Molecular Imaging, Center for Neuroendocrine Tumors Bad Berka-ENETS Center of Excellence, Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9, 99437 Bad Berka, BRD, Germany.

Molecular imaging with ⁶⁸Ga-SSTR PET/CT and correlation to immunohistochemistry of somatostatin receptors in neuroendocrine tumours.
Eur J Nucl Med Mol Imaging 2011 Sep 31;38(9):1659-68. Epub 2011 May 31.
Department of General and Visceral Surgery, Zentralklinik Bad Berka GmbH, Robert-Koch-Allee 9, 99437 Bad Berka, Germany.

Phase 3 Trial ofLu-Dotatate for Midgut Neuroendocrine Tumors.
N Engl J Med 2017 01;376(2):125-135
From the Moffitt Cancer Center, Tampa, FL (J.S., G.E.-H.); Markey Cancer Center, University of Kentucky, Lexington (E.W.); Cedars Sinai Medical Center, Los Angeles (A.H.), and Stanford University School of Medicine, Stanford (E.M., P.L.K.) - both in California; University of Texas M.D. Anderson Cancer Center (J.Y., B.C.) and Excel Diagnostics Imaging Clinic (E.D.), Houston; Dana-Farber Cancer Institute, Boston (M.H.K., H.J.); University of Iowa, Iowa City (D.B., T.M.O.); Zentralklinik, Bad Berka (R.P.B., H.R.K.), and Charité-Universitätsmedizin, Berlin (M.P.) - both in Germany; Royal Free Hospital (M.C.) and King's College Hospital NHS Foundation Trust (R.S.), London, and Beatson Oncology Centre, Glasgow (N.R.) - all in the United Kingdom; Hôpital Beaujon, Clichy (R.L., P.R.), and Advanced Accelerator Applications, St. Genis-Pouilly (T.T.) - both in France; Mayo Clinic College of Medicine, Rochester, MN (T.H.); University Hospitals and KU Leuven, Leuven, Belgium (E.V.C.); Robert H. Lurie Comprehensive Cancer Center, Chicago (A.B.); Hospital Universitari de Bellvitge, Barcelona (J.M.), and Hospital Universitario Ramón y Cajal, Madrid (E.G.) - both in Spain; Vanderbilt University Medical Center, Nashville (J.B.); Fondazione Istituto di Ricovero e Cura a Carattere Scientifico Istituto Nazionale dei Tumori, Milan (E.S.); University Hospital, Uppsala University, Uppsala, Sweden (K.O.); Advanced Accelerator Applications USA, New York (M.L.S., P.S., J.L.E.); and Erasmus Medical Center, Rotterdam, the Netherlands (D.K., E.K.).

OF